J&J Seeks Europe Okay for Spravato in Imminent Suicide Risk
January 15 2020 - 8:25AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Wednesday said it filed with the European Medicines Agency for
expanded use of its Spravato nasal spray in adults at imminent risk
for suicide.
The drug maker said it is seeking European approval for Spravato
as an acute short-term treatment, co-administered with oral
antidepressant therapy, for the rapid reduction of depressive
symptoms in adults with a moderate-to-severe depressive episode of
major depressive disorder who have current suicidal ideation with
intent.
The European Commission last month approved Spravato for adults
with treatment-resistant major depressive disorder.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 15, 2020 08:10 ET (13:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
